CVS to buy Aetna for $69 billion; J&J buys commercial rights for biotech's experimental hypertension drug; Republicans repeal Obamacare's individual mandate
Pfizer Q3 revenue driven by Prevnar sales; President Trump's opioid panel presents draft to combat crisis; Novartis seeks FDA approval for CAR-T therapy Kymriah
No crucial area in pharma is more desperately in need of a fix — or more stubbornly resistant to change.
Trump administration considers outcomes-based approach to lower drug prices; Sanofi to acquire vaccines biotech; Nestle partners with Enterome to develop microbiome-based diagnostics
Adamis receives FDA approval for EpiPen rival Symjepi; Clovis reports positive trial results for ovarian cancer drug Rubraca; hedge fund billionaire John Paulson joins Valeant board of directors
Google invests in European biotechs; hospitals that restrict sales-rep visits more likely to prescribe cheaper generics; AI could help doctors with new research
Biogen completes hemophilia spinoff; old drug being tested as a prostate cancer treatment; Merck reports Q4 decline in revenue
Drug spending projected to grow at 6% clip through 2024, spurred in part by pricey new medications; FDA approves new obesity device; Sanofi diabetes combo drug is better at reducing blood glucose than Lantus.
Merck will collaborate with Syndax to evaluate the pairing of an anti-PD-1 therapy in Keytruda with HDAC inhibitor entinostat.
The personal genetics company created a therapeutics group to extricate new drug targets from its research database.